Millipore now offers 17 lipid kinases, said to be more than any other company, both for purchase and as part of its gold-standard KinaseProfiler service
Lipid kinases are one of the most promising new classes of potential drug targets.
PI3 kinases regulate a wide variety of cellular functions, including cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking.
As a result, defects in PI3 kinase function lead to multiple disease states, including several forms of cancer.
Millipore's newly-expanded lipid kinase panel and KinaseProfiler service provide the tools to dissect the networks underlying PI3 kinase signaling, essential to the design of new therapies.
Combined with Millipore's PI3 kinase HTRF assay, KinaseProfiler service, and small-molecule inhibitors, the expanded lipid kinase panel provides researchers with the most complete way of studying lipid kinase signaling.
The new lipid kinase panel includes both wild type and disease-linked mutants.
Established in 1954 as a high performance filtration products and services company, Millipore has grown into a partner for life science customers through R+D investment, organic growth and acquisitions.
Companies acquired include Chemicon, Upstate, Linco, and NovaSeptic.
The integrated Millipore offers more innovative technologies and stronger application support to streamline progress and give more confidence in results.